_parp-inhibitors-for-ovarian-cancer-preview-1.jpg "PARP inhibitors for ovarian cancer from parp Video Screenshot Preview 1")
Gallery_parp-inhibitors-for-ovarian-cancer-preview-3.jpg "PARP inhibitors for ovarian cancer from parp Video Screenshot Preview 3")
Gallery_parp-inhibitors-for-ovarian-cancer-preview-hqdefault.jpg "PARP inhibitors for ovarian cancer from parp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 3 minutes 45 seconds
👁 View: 190 times
Play Audio:👁 View: 190 times
Description:
VJOncology
VJOncology
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.webp "UCLA Health")
⏲ 34 minutes 17 seconds 👁 4.6K
_parp-inhibitors-revolutionising-cancer-treatment.webp "astrazeneca")
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.webp "Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.")
_an-overview-of-parp-inhibitors-in-ovarian-cancer.webp "Targeted Oncology")
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.webp "Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.")
_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023.webp "Touch Medical Media Services")
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.webp "James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.")
⏲ 2 min 33 sec ✓ 28-Jan-2018
_ctsc-124-stenoparib-and-covid-19.webp "Stenoparib Publication in MBio JournalnnStenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 and HCoV-NL63 human coronaviruses in vitro.nnMore info: https://joinpmi.com/ctsc-stenoparib-and-covid-19")
_parp-inhibitors-for-the-treatment-of-ovarian-cancer-gottfried-konecny-md-124-uclamdchat.jpg)
_parp-inhibitors-revolutionising-cancer-treatment.jpg)
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.jpg)
_an-overview-of-parp-inhibitors-in-ovarian-cancer.jpg)
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.jpg)
_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023.jpg)
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.jpg)
_ctsc-124-stenoparib-and-covid-19.jpg)
![[+]](/images/menu.gif){kind=small}